Comparative Pharmacology
Head-to-head clinical analysis: CYTOVENE versus FLUMADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOVENE versus FLUMADINE.
CYTOVENE vs FLUMADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanosine analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporation into viral DNA, causing chain termination. It is phosphorylated intracellularly to ganciclovir triphosphate, which is active against cytomegalovirus (CMV).
Rimantadine inhibits the replication of influenza A virus by blocking the M2 ion channel, thereby preventing viral uncoating and the release of viral RNA into host cells. It also has weak NMDA receptor antagonist properties.
Induction: 5 mg/kg IV every 12 hours for 14-21 days; maintenance: 5 mg/kg IV once daily for 7 days per week or 6 mg/kg IV once daily for 5 days per week
100 mg orally twice daily for 7-10 days; initiate within 48 hours of symptom onset.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 28-40 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life: 16-48 hours (mean ~24 hours). In elderly (>70 years) or severe renal impairment (CrCl <10 mL/min), half-life may exceed 100 hours, requiring dose reduction.
Primarily renal excretion as unchanged drug (>90%); 1-2% biliary/fecal
Renal: 85% unchanged via glomerular filtration and tubular secretion; Fecal: <5%
Category C
Category C
Antiviral Agent
Antiviral Agent